Main content

    Hematologic Oncology Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov



    Leukemia  |  Lymphoma  |  Multiple Myeloma


    Active Trials

    Leukemia

    Title: A Randomized Phase II Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacititdine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
    Decscription: Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with a morphologically confirmed diagnosis of myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML)
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study SWOG S1117

    Back to top

    Lymphoma

    Title: A Phase 1/2 single-arm, open-label study to evaluate the safety and efficacy of brentuximab vedotin in combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma (HL)
    Decscription: To assess the safety and tolerability of brentuximab vedotin in combination with bendamustine at the recommended dosing level
    Investigator: Caroline Behler, MD
    Eligibility: Subjects, 18 y/o and older, with documented histopathological diagnosis of classical HL excluding nodular lymphocyte predominant HL (NLPHL)
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study SGN35-016

    Back to top

    Multiple Myeloma

    Title: A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
    Decscription: Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)
    Investigator: Caroline Behler, MD
    Eligibility: Subjects, 18 y/o and older, who are newly diagnosed with symptomatic Multiple Myeloma (MM)
    Status: Coming soon
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study BMS CA204-006

    • updated January 2014

    Back to top